Jane Street’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.22M Sell
191,100
-55,500
-23% -$1.78M ﹤0.01% 3188
2025
Q4
$8.68M Sell
246,600
-48,800
-17% -$1.73M ﹤0.01% 2496
2025
Q3
$7.76M Buy
295,400
+201,800
+216% +$6.02M ﹤0.01% 2761
2025
Q2
$2.48M Sell
93,600
-58,500
-38% -$1.54M ﹤0.01% 4082
2025
Q1
$3.67M Sell
152,100
-129,700
-46% -$4.1M ﹤0.01% 3392
2024
Q4
$11.3M Sell
281,800
-57,000
-17% -$3.25M ﹤0.01% 1764
2024
Q3
$21.4M Buy
338,800
+142,000
+72% +$8.33M ﹤0.01% 1192
2024
Q2
$10.4M Sell
196,800
-66,500
-25% -$4.36M ﹤0.01% 2013
2024
Q1
$21.6M Buy
263,300
+199,900
+315% +$8.89M ﹤0.01% 1128
2023
Q4
$1.18M Buy
63,400
+30,700
+94% +$401K ﹤0.01% 5270
2023
Q3
$362K Sell
32,700
-67,900
-67% -$971K ﹤0.01% 6764
2023
Q2
$1.63M Sell
100,600
-28,800
-22% -$603K ﹤0.01% 4472
2023
Q1
$2.15M Buy
129,400
+91,800
+244% +$948K ﹤0.01% 3696
2022
Q4
$353K Buy
+37,600
New +$168K ﹤0.01% 6736
2021
Q3
Sell
-21,300
Closed -$128K 10796
2021
Q2
$128K Sell
21,300
-22,000
-51% -$131K ﹤0.01% 9149
2021
Q1
$274K Buy
43,300
+26,500
+158% +$186K ﹤0.01% 7822
2020
Q4
$95K Buy
16,800
+600
+4% +$3.63K ﹤0.01% 7217
2020
Q3
$94K Sell
16,200
-1,300
-7% -$8.95K ﹤0.01% 6771
2020
Q2
$126K Buy
+17,500
New +$116K ﹤0.01% 6625
2018
Q4
Sell
-40,100
Closed -$699K 5777
2018
Q3
$699K Buy
+40,100
New +$477K ﹤0.01% 3207

Other funds holding VKTX

Jane Street's VKTX Position: Q1 2026 in Review

Jane Street reduced its Viking Therapeutics (VKTX) stake by 50% in Q1 2026, selling an estimated $24.2M and leaving 748,949 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1612.

Jane Street first reported a position in VKTX in Q3 2018 and has held it in 29 quarters since. The position peaked at $52.8M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Jane Street held 748,949 shares of Viking Therapeutics worth $24.4M as of Q1 2026.
  • Jane Street sold 752,168 Viking Therapeutics shares in Q1 2026, an estimated $24.2M.
  • Viking Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1612 holding.
  • Jane Street first reported a position in Viking Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Jane Street's Viking Therapeutics position peaked at $52.8M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.